Precision BioSciences, Inc. (DTIL) Dividend History

Company News

• CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

  The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

  GlobeNewswire Inc.

  Featured Companies: ACLX ALLO IPSC KYTX RNAC SANA
• Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82%

  The global genetic engineering market is expected to grow from USD 1.35 billion in 2023 to USD 8.95 billion by 2033, driven by the increasing demand for biopharmaceutical products made through genetically altered processes. However, the high cost of R&D is a restraint on market growth.

  GlobeNewswire Inc.

  Featured Companies: A CBUS CRBU CRSP NTLA SGMO TMO
• Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%

  The gene editing therapeutics market is expected to grow significantly, reaching $1 billion by 2029 with a CAGR of 147%. Key drivers include the increasing prevalence of chronic and rare genetic diseases, as well as the need for precision medicine.

  GlobeNewswire Inc.

  Featured Companies: ALLO BEAM CRBU CRSP EDIT NTLA SGMO VOR VRTX
• Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?

  The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  Zacks Investment Research
• Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)

  In the latest quarter, 4 analysts provided ratings for Precision BioSciences (NASDAQ:DTIL), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $49.75, along with a high estimate of $60.00 and a low estimate of $19.00. Observing a 1558.33% increase, the current average has risen from the previous average price target of $3.00. Deciphering Analyst Ratings: An In-Depth Analysis The standing of Precision BioSciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Patrick Trucchio HC Wainwright & Co. Maintains Buy $60.00 - Debjit Chattopadhyay Guggenheim Announces Buy $19.00 - Patrick Trucchio HC Wainwright & Co. Maintains Buy $60.00 - Patrick Trucchio HC Wainwright & Co. Adjusts Buy $60.00 $3.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Precision BioSciences. This information provides a snapshot of how analysts perceive ...Full story available on Benzinga.com

  Benzinga